Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Afatinib vs Trastuzumab vs Lapatinib in HER2+ Breast Cancer
NCT00826267Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2009
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of afatinib in breast cancer, sponsored by Boehringer Ingelheim. Started Jan 2009; status: completed.
02
Drugs
afatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00826267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00826267.